Argus
•
Apr 22, 2026
BMRN: Lowering target price to $60.00
Summary
BioMarin is a global biotechnology company focused on developing and commercializing thera
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Analyst Report: Illumina, Inc.
May 01, 2026
•
ILMN
Analyst Report: Alnylam Pharmaceuticals, Inc.
May 01, 2026
•
ALNY
Analyst Report: Amgen Inc.
May 01, 2026
•
AMGN
Analyst Report: Merck & Co., Inc.
May 01, 2026
•
MRK
Analyst Report: Ionis Pharmaceuticals, Inc.
Apr 30, 2026
•
IONS
